Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the first strategic decisions is choosing the right market authorization structure. For foreign pharma and biotech companies, the question often becomes: should you build your own MAH setup, appoint a DMAH, or choose another route entirely? It sounds technical, but this decision affects control, speed, cost, governance, and long-term value. In other words, it is not just regulatory housekeeping. It is part of your business model for Japan. The tricky part is that the choice must often be made before market entry, when certainty is still limited.
What is a MAH, and what is a DMAH?
In Japan, a MAH, Marketing Authorization Holder, is the Japan-based legal entity that holds the product approval and carries local responsibility for quality and safety. This includes obligations linked to GQP, GVP, and release-to-market accountability. A DMAH, Designated Marketing Authorization Holder, is a Japan-based MAH that a foreign company designates to act locally on its behalf. The practical point is simple: a foreign company cannot avoid the need for a Japan-side holder. It must either build that capability itself or appoint it externally. Japan therefore forces an earlier and more practical structure decision than many companies expect.
What need to be factored in to your choice
Choosing your own MAH gives maximum control. It is usually the strongest long-term option if Japan is a core market, if multiple products are planned, or if lifecycle management and pricing strategy matter deeply. But it also demands the highest investment, the most internal buildout, and the greatest management burden. A third-party DMAH offers faster entry, lower fixed overhead, and immediate access to local execution, which can be highly attractive for lean biotechs or companies still testing the Japan opportunity. The tradeoff is reduced control, more contractual complexity, and possible disruption if the MAH role is transferred later. The article makes clear that this is not a simple regulatory preference. It is a strategic tradeoff between control and speed.
Yes, there is a third alternative
There is also a third option, and it is often overlooked in early discussions: partner with or license to a Japanese pharma company that becomes the MAH. This route is very different from a pure DMAH service model. Here, the local company is not only the holder, but often also the commercial and medical engine in Japan. It can be the strongest execution model for companies that want local reach without building a direct business immediately. But it also means giving up more control over strategy, positioning, and economics. In many cases, this is less a regulatory decision and more a business model choice.
Make the choice consciously
The right answer depends on three questions: Is Japan a core market or an opportunistic one? How much control do you need over the asset? How many products are coming? For a small biotech with one asset, DMAH or a Japanese commercialization partner may be rational. For a mid-size or large pharma with serious Japan ambition, building your own MAH platform may create far more long-term value. The key is not to drift into a structure by default. Make the choice consciously, before market entry, and in line with your strategy. To explore the tradeoffs in more detail, download and read our full article from Biosector’s homepage.
Here, you can download our PDF cheatsheet with the strategic considerations you need to think deeply about.
Comments are closed